Literature DB >> 33672786

Characterization of the GBoV1 Capsid and Its Antibody Interactions.

Jennifer Chun Yu1, Mario Mietzsch1, Amriti Singh1, Alberto Jimenez Ybargollin1, Shweta Kailasan1, Paul Chipman1, Nilakshee Bhattacharya2, Julia Fakhiri3, Dirk Grimm3, Amit Kapoor4, Indrė Kučinskaitė-Kodzė5, Aurelija Žvirblienė5, Maria Söderlund-Venermo6, Robert McKenna1, Mavis Agbandje-McKenna1.   

Abstract

Human bocavirus 1 (HBoV1) has gained attention as a gene delivery vector with its ability to infect polarized human airway epithelia and 5.5 kb genome packaging capacity. Gorilla bocavirus 1 (GBoV1) VP3 shares 86% amino acid sequence identity with HBoV1 but has better transduction efficiency in several human cell types. Here, we report the capsid structure of GBoV1 determined to 2.76 Å resolution using cryo-electron microscopy (cryo-EM) and its interaction with mouse monoclonal antibodies (mAbs) and human sera. GBoV1 shares capsid surface morphologies with other parvoviruses, with a channel at the 5-fold symmetry axis, protrusions surrounding the 3-fold axis and a depression at the 2-fold axis. A 2/5-fold wall separates the 2-fold and 5-fold axes. Compared to HBoV1, differences are localized to the 3-fold protrusions. Consistently, native dot immunoblots and cryo-EM showed cross-reactivity and binding, respectively, by a 5-fold targeted HBoV1 mAb, 15C6. Surprisingly, recognition was observed for one out of three 3-fold targeted mAbs, 12C1, indicating some structural similarity at this region. In addition, GBoV1, tested against 40 human sera, showed the similar rates of seropositivity as HBoV1. Immunogenic reactivity against parvoviral vectors is a significant barrier to efficient gene delivery. This study is a step towards optimizing bocaparvovirus vectors with antibody escape properties.

Entities:  

Keywords:  antigenicity; bocavirus; capsid; cryo-EM; gene therapy; parvovirus

Mesh:

Substances:

Year:  2021        PMID: 33672786      PMCID: PMC7924616          DOI: 10.3390/v13020330

Source DB:  PubMed          Journal:  Viruses        ISSN: 1999-4915            Impact factor:   5.818


  49 in total

1.  Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses.

Authors:  Roberto Calcedo; Luk H Vandenberghe; Guangping Gao; Jianping Lin; James M Wilson
Journal:  J Infect Dis       Date:  2009-02-01       Impact factor: 5.226

2.  Structural Insights into Human Bocaparvoviruses.

Authors:  Mario Mietzsch; Shweta Kailasan; Jamie Garrison; Maria Ilyas; Paul Chipman; Kalle Kantola; Mandy E Janssen; John Spear; Duncan Sousa; Robert McKenna; Kevin Brown; Maria Söderlund-Venermo; Timothy Baker; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2017-05-12       Impact factor: 5.103

3.  pH-Induced Conformational Changes of Human Bocavirus Capsids.

Authors:  Mengxiao Luo; Mario Mietzsch; Paul Chipman; Kangkang Song; Chen Xu; John Spear; Duncan Sousa; Robert McKenna; Maria Söderlund-Venermo; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2021-01-20       Impact factor: 5.103

4.  Original antigenic sin with human bocaviruses 1-4.

Authors:  Xuemeng Li; Kalle Kantola; Lea Hedman; Benedict Arku; Klaus Hedman; Maria Söderlund-Venermo
Journal:  J Gen Virol       Date:  2015-07-28       Impact factor: 3.891

5.  A novel chimeric adenoassociated virus 2/human bocavirus 1 parvovirus vector efficiently transduces human airway epithelia.

Authors:  Ziying Yan; Nicholas W Keiser; Yi Song; Xuefeng Deng; Fang Cheng; Jianming Qiu; John F Engelhardt
Journal:  Mol Ther       Date:  2013-07-30       Impact factor: 11.454

6.  Human bocavirus can be cultured in differentiated human airway epithelial cells.

Authors:  Ronald Dijkman; Sylvie M Koekkoek; Richard Molenkamp; Oliver Schildgen; Lia van der Hoek
Journal:  J Virol       Date:  2009-05-27       Impact factor: 5.103

7.  Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial.

Authors:  Richard B Moss; Carlos Milla; John Colombo; Frank Accurso; Pamela L Zeitlin; John P Clancy; L Terry Spencer; Joseph Pilewski; David A Waltz; Henry L Dorkin; Thomas Ferkol; Mark Pian; Bonnie Ramsey; Barrie J Carter; Dana B Martin; Alison E Heald
Journal:  Hum Gene Ther       Date:  2007-08       Impact factor: 5.695

Review 8.  Twenty-Five Years of Structural Parvovirology.

Authors:  Mario Mietzsch; Judit J Pénzes; Mavis Agbandje-McKenna
Journal:  Viruses       Date:  2019-04-20       Impact factor: 5.048

9.  Novel Chimeric Gene Therapy Vectors Based on Adeno-Associated Virus and Four Different Mammalian Bocaviruses.

Authors:  Julia Fakhiri; Marc A Schneider; Jens Puschhof; Megan Stanifer; Verena Schildgen; Stefan Holderbach; Yannik Voss; Jihad El Andari; Oliver Schildgen; Steeve Boulant; Michael Meister; Hans Clevers; Ziying Yan; Jianming Qiu; Dirk Grimm
Journal:  Mol Ther Methods Clin Dev       Date:  2019-01-18       Impact factor: 6.698

10.  ICTV Virus Taxonomy Profile: Parvoviridae.

Authors:  Susan F Cotmore; Mavis Agbandje-McKenna; Marta Canuti; John A Chiorini; Anna-Maria Eis-Hubinger; Joseph Hughes; Mario Mietzsch; Sejal Modha; Mylène Ogliastro; Judit J Pénzes; David J Pintel; Jianming Qiu; Maria Soderlund-Venermo; Peter Tattersall; Peter Tijssen
Journal:  J Gen Virol       Date:  2019-01-23       Impact factor: 3.891

View more
  3 in total

1.  Characterization of the Serpentine Adeno-Associated Virus (SAAV) Capsid Structure: Receptor Interactions and Antigenicity.

Authors:  Mario Mietzsch; Joshua A Hull; Victoria E Makal; Alberto Jimenez Ybargollin; Jennifer C Yu; Kedrick McKissock; Antonette Bennett; Judit Penzes; Bridget Lins-Austin; Qian Yu; Paul Chipman; Nilakshee Bhattacharya; Duncan Sousa; David Strugatsky; Peter Tijssen; Robert McKenna; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2022-05-09       Impact factor: 6.549

Review 2.  Small but mighty: old and new parvoviruses of veterinary significance.

Authors:  Mason C Jager; Joy E Tomlinson; Robert A Lopez-Astacio; Colin R Parrish; Gerlinde R Van de Walle
Journal:  Virol J       Date:  2021-10-24       Impact factor: 4.099

Review 3.  Next-Generation Gene Therapy for Parkinson's Disease Using Engineered Viral Vectors.

Authors:  Tomas Björklund; Marcus Davidsson
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.